Diabetic Nephropathy Market

Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020

Diabetic Nephropathy Market Segmented By Angiotensin-Converting Enzyme Inhibitors, Diuretics, Calcium Channel Blockers, Renin Inhibitors, Connective Tissue Growth Factor Inhibitors, Antioxidant Inflammation Modulator, Monocyte Chemoattractant Proteins Inhibitor, Endothelin-A Receptor Antagonist

  • September-2020
  • PMRREP3594
  • 106 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Introduction

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria.

The global DMT market reached USD 2,093.5 million in 2014 and USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020.

Find Out More about the Report Coverage

Companies

Some of the major players in the diabetic nephropathy market:

  • Novartis AG, Merck & Co., Inc.
  • Pfizer, Inc.
  • Abbott Laboratories.
  • Sanofi.
  • Eli Lilly.
  • Company.
  • Reata Pharmaceuticals, Inc.
  • Bayer AG, AbbVie, Inc.
  • Mitsubishi Tanabe Pharma Corporation.
  • Other

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Market Drivers

Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. 

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

By Geography

North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy. 

North American market reached USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Media Release

Recommendations

Life Sciences Aggregate-Spending Market

The global life sciences aggregate-spending market was pegged at US$ 974.2 Mn in 2021, with a projected CAGR of 10% for the forecast period (2022-2032).

Cell Culture Media Market

The global cell culture media market was valued at US$ 2.6 Bn in 2020, and is projected to reach a valuation of US$ 5.6 Bn by 2031..

North America Synthetic Opioids Market

Globally, semi-synthetic opioids segment accounted for more than 90% revenue share of the industry in 2016 and is expected to gain more than 10 BPS in its market share by 2024.

Bone Marrow Transplantation Market

Bone Marrow Transplant Market is expected to exceed US$ 12 Bn by the end of 2028. The bone marrow transplantation market is expected to grow at a CAGR of 3.6% through the forecast period 2018-2028..

Our Clients

Our Clients